Key takeaways
- GHK-Cu is the tripeptide Gly-His-Lys bound to copper(II); Matrixyl is palmitoyl pentapeptide-4, the procollagen fragment KTTKS with a palmitoyl chain and no copper.
- Matrixyl 3000 is a different product: palmitoyl tripeptide-1 (GHK with a palmitoyl chain, no copper) with palmitoyl tetrapeptide-7.
- Human evidence for both as cosmetics is small: for GHK-Cu, small skin studies and one PubMed-indexed randomised trial of a skin-care regimen that found no objective difference, though patients rated their skin higher; for Matrixyl, two randomised cream trials, of 93 and 21 women.
- We found no study comparing GHK-Cu with Matrixyl; one small 2016 study against Matrixyl 3000 is known only through a review by GHK’s discoverer.
- Both are cosmetic ingredients; GHK-Cu also appears on FDA’s compounding lists and among the TGA’s examples of unapproved peptide products, and Matrixyl does not.
01How do GHK-Cu and Matrixyl differ?
The same questions for both, dated 18 November 2026.
| Question | GHK-Cu | Matrixyl |
|---|---|---|
| What it is | Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK) | Trade name for palmitoyl pentapeptide-4: the five amino acids Lys-Thr-Thr-Lys-Ser (KTTKS) with a palmitoyl fatty-acid chain |
| Cosmetic ingredient (INCI) name | Copper tripeptide-1 | Palmitoyl pentapeptide-4 (palmitoyl pentapeptide-3 before 2006) |
| Contains copper | Yes | No |
| Where the sequence comes from | GHK was reported in human serum in 1973 | KTTKS is a stretch of the type I procollagen propeptide, described in 1993 |
| Type, as reviews sort them | Carrier peptide | Signal peptide |
| Related product | — | Matrixyl 3000: palmitoyl tripeptide-1 (GHK with a palmitoyl chain, no copper) with palmitoyl tetrapeptide-7 |
| PubMed records naming it (18 Nov 2026) | 105 | 38 for Matrixyl or palmitoyl pentapeptide names; 12 for Matrixyl 3000 or its two components; 48 in all |
| Laboratory evidence | Cell and animal studies (T4, T3) | Cell studies of KTTKS and its palmitoyl form (T4) |
| Human studies we cite | Small skin studies, mostly conference posters; one PubMed-indexed randomised trial with 13 completers that found no objective difference | Two randomised single-ingredient cream trials (93 women, 12 weeks; 21 women, 8 weeks) and multi-ingredient product trials |
| Independent assessment | 2026 evidence-map review: clinical evidence “remains sparse” | 2011 review of KTTKS and its derivatives: “relatively few clinical studies” |
| Cosmetic Ingredient Review (industry-funded, cosmetic use only) | Copper tripeptide-1 is in its 2018 assessment | Not named in that assessment; both Matrixyl 3000 components are |
| FDA compounding lists | Injectable routes: among withdrawn Category 2 nominations. Other routes: back in Category 1, under evaluation (May 2026) | Not listed |
| Australia (TGA advisory, Apr 2026) | Products containing it named among examples of unapproved peptide products | Not named |
| WADA | Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited”; anti-doping organisations decide how class S0 applies | Not named on the 2026 or 2027 List; WADA’s 2027 notes say an unnamed peptide “may still be prohibited”; anti-doping organisations decide how class S0 applies |
02What is GHK-Cu?
GHK-Cu is a three-amino-acid peptide, glycine–histidine–lysine, bound one to one to copper(II). In cosmetics it is listed as copper tripeptide-1, and prezatide copper is another name for it. GHK was reported in human serum in 1973 by Loren Pickart and M. M. Thaler, and its binding to copper was described from 1980. A 2026 review describes it as an endogenous tripeptide, and reviews of skincare peptides class it as a carrier peptide, one designed to carry substances skin cells use, such as copper.
It has a second life outside cosmetics. FDA’s compounding lists name it, and Australia’s TGA names products containing it among its examples of unapproved peptide products, “often supplied in injectable form”. The research: GHK-Cu research guide.
03What is Matrixyl?
The sequence. In 1993, researchers at the University of Tennessee reported that a five-amino-acid stretch of the type I procollagen propeptide, Lys-Thr-Thr-Lys-Ser, was the shortest sequence active in their fibroblast-culture experiments on matrix production. That is a cell study (T4).
The ingredient. Adding a palmitoyl chain, a 16-carbon fatty acid, gives pal-KTTKS, described in a 2019 paper as “a more stable form of KTTKS”. The same paper says it went on the market in 2000 as the active ingredient of Matrixyl, made by Sederma in France, and that its ingredient name was palmitoyl pentapeptide-3 before 2006. A 2020 review places Sederma within Croda International. Reviews class it as a signal peptide, designed to act as a signal to skin cells that make structural proteins such as collagen.
Matrixyl 3000 is a different product. It pairs palmitoyl tripeptide-1 with palmitoyl tetrapeptide-7, also called pal-GHK and pal-GQPR. Palmitoyl tripeptide-1 is the GHK sequence with a palmitoyl chain and no copper. So Matrixyl 3000 shares a sequence with GHK-Cu, not an ingredient. More on the peptide types: peptides in skincare.
04How have GHK-Cu and Matrixyl been studied?
Unevenly, and often by people with a commercial interest in them. Laboratory findings are not evidence of an effect in people, and we give designs, not results.
GHK-Cu. Most research is in cells and animals. The human studies of it as a cosmetic applied it to the skin: small, short studies, most reported as conference posters and known mainly through a 2018 review by GHK’s discoverer, and one PubMed-indexed randomised trial of a skin-care regimen after laser resurfacing, in which 13 people completed and computer analysis and blinded evaluators found no significant difference, though patients rated their skin higher. A 2026 systematic review found that about 35% of the GHK-Cu primary literature it included lists Pickart or Anna Margolina of Skin Biology Inc. as authors. Detail: topical GHK-Cu.
Matrixyl. The cell work is on KTTKS and its palmitoyl form. In people we found two randomised trials of a cream containing palmitoyl pentapeptide-4 on its own. In 2005, a trial run at Procter & Gamble had 93 women aged 35 to 55 use a moisturiser with it on one side of the face and without it on the other, for 12 weeks, and measured wrinkles and fine lines in facial images. In 2023, a dermatology department in Jakarta randomised 21 women aged 26 to 55 to a palmitoyl pentapeptide-4 cream, an acetyl hexapeptide-3 cream or placebo for 8 weeks, measuring skin hydration, water loss, elasticity, photographs and a crow’s-feet grade. Other trials tested products that combine it with several active ingredients, which cannot separate its contribution.
Matrixyl 3000. We found no PubMed record of a randomised trial of it on its own (title and abstract search, 18 November 2026).
Independent reviewers. A 2026 evidence-map review, whose authors declare no conflicts, wrote that GHK-Cu’s clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”. A 2011 review of KTTKS and its derivatives, from Cardiff University, found “a surprising absence of in vitro skin penetration data in the literature, and there are relatively few clinical studies using these materials.” In its assessment of trial limits, a 2026 review of skincare peptides wrote that “many trials are limited by small samples, short follow-up, industry sponsorship, or multi-ingredient formulations”, and that palmitoyl pentapeptide-4 “should not be equated with hydrolyzed collagen or a placenta-derived peptide mixture”.
05What research compared them directly?
One small study, which we could not read. A 2018 review co-written by GHK’s discoverer describes a randomised, double-blind, 8-week study by Badenhorst and colleagues (2016) in female volunteers: GHK-Cu in a nano-lipid carrier against the carrier alone and against Matrixyl 3000. It appeared in the Journal of Aging Science, is not indexed in PubMed, and is known to us only through that review. It compared GHK-Cu with Matrixyl 3000, not with Matrixyl.
Three PubMed records name both GHK-Cu and Matrixyl or its components (18 November 2026): two reviews and a cell study of a different, palmitoylated copper peptide. None tested one against the other. We found no study comparing GHK-Cu with palmitoyl pentapeptide-4.
06How are GHK-Cu and Matrixyl regulated?
In a cosmetic, both fall under the same product rules. The differences are in what panels and regulators have named.
Cosmetic rules. FDA says “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”. That applies to a cream with either peptide. How the EU, Great Britain and Australia treat cosmetics: peptides in skincare.
Cosmetic Ingredient Review. In 2018 this panel, which the cosmetics industry’s trade association set up and funds and which describes its process as independent, assessed tripeptide-1, its metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7. Its summary names copper tripeptide-1, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 among those used in cosmetic products, so it covers GHK-Cu and both Matrixyl 3000 components. Its conclusion is limited to “the present practices of use and concentration described in this safety assessment”, in which typical use concentrations were in the parts-per-million range, and covers cosmetic use only. Palmitoyl pentapeptide-4 is not named in that summary.
Medicines regulators. FDA’s compounding page (content current 22 April 2026) lists GHK-Cu for injectable routes among substances previously in Category 2 whose nominations were withdrawn, citing possible immune reactions. FDA’s list of 14 May 2026 puts GHK-Cu, except injectable routes, back in Category 1, under evaluation. Neither page names palmitoyl pentapeptide-4, Matrixyl or KTTKS. The TGA’s April 2026 advisory names products containing GHK-Cu among its examples of unapproved peptide products; its examples do not include the others. No medicine containing either appears in Drugs@FDA (18 November 2026).
Sport. Neither is named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers pharmacological substances with no current government approval for human therapeutic use, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how it applies.
07What we don’t know about GHK-Cu and Matrixyl
- How the two compare. We found no study of GHK-Cu against Matrixyl, and could not read the one against Matrixyl 3000.
- How much of either reaches living skin cells in people from a cream.
- Whether a result for one product applies to another with the same peptide. Formulations, strengths and other ingredients differ.
- How either behaves over years of use. The trials we cite lasted 8 to 12 weeks.
- Current EU inventory entries for either name. The EU’s CosIng database did not load for our tools.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.